Abstract: Over 60,000 individuals undergo solid organ or hematopoietic cell transplantation in the United States each year. Because the lungs are both exposed to the contaminated environment of ambient air and a relative hotbed of immunologic activity even in health, pulmonary complications are common and important in this clinical context. Lung transplantation and allogeneic bone marrow transplantation are the focus of this paper since pulmonary complications are most common and most devastating in these situations. Both infectious and noninfectious inflammatory complications are examined from both diagnostic and therapeutic points of view. Acute and chronic graft rejection remains a significant barrier to long-term survival after lung transplantation. Pulmonary complications after bone marrow transplantation are highly time dependent and continue to cause significant morbidity. The similarities and differences between bronchiolitis obliterans associated with chronic graft versus host disease and lung transplantation are briefly outlined. We also emphasize recent developments that hopefully will lead to improved outcomes in the 21 st century.
A lmost 20,000 individuals in the United States undergo organ transplantation each year. As of 2004, the United Network for Organ Sharing collects data with regard to 8 different kinds of solid organ transplants. Despite the absence of a definitive hematopoietic registry, it is estimated that each year 40,000 individuals around the world undergo some form of hematopoietic cell transplantation (we will use the generic term BMT in this paper). Solid organ transplant and BMT recipients both receive immunosuppression and experience a critical condition of vulnerability in the immediate posttransplant period. Because the lung is an organ susceptible to infection and immunologic injury in normal individuals, logically, in the transplant context, the lung is a site of significant complications. For reasons of simplification, we focus in this paper on specific pulmonary complications, which are encountered in lung transplantation and BMT. We emphasize aspects that are likely to be of interest and relevance to the general pulmonary physician. We also highlight developments reflecting recent or imminent changes in clinical practice.
Lung Transplantation
Approximately 1000 lung transplant procedures are performed in the United States per year since the year 2000, 1 and over 1500 procedures were performed worldwide in 2001 and 2002. 2 The primary indications for lung transplantation are shown in Table 1 . Chronic obstructive lung disease is the leading disease treated with lung transplantation in adults. 1, 2 Cystic fibrosis and idiopathic pulmonary fibrosis each account for approximately one sixth of lung-transplant recipients. In children, cystic fibrosis is the leading indication, with pulmonary vascular disease with or without congenital heart disease second. 3 Complications of lung transplantation can be generally segregated by time periods after the surgery (Fig. 1) . Although allograft rejection and infection are the major causes of both morbidity and mortality after lung transplantation, as with other organ transplants, the complexities of the events after transplantation often lead to an overlap of a variety of factors, which have been more definitively described elsewhere. 4 
Primary Graft Failure
A primary reason for the vulnerability of the lung to injury and dysfunction immediately after reimplantation is its enormous vascular surface area and the susceptibility of its capillary bed to injury after resumption of blood flow and ventilation. Most transplant surgeons aim to keep the socalled ischemia time (time between harvest in the donor and recirculation and ventilation in the recipient) to 6 hours or less to minimize organ injury. Primary graft failure (PGF) is a recently coined term to account for the condition in lungtransplant recipients who experience hypoxemic respiratory failure in the first 1 to 3 days after lung transplantation. 5 Because of a difference in definition and perhaps clinical management, the incidence of PGF in the published literature ranges from 13% to 50%. 5, 6 Risk factors also vary among studies. Ischemic time does not always correlate with PGF, but early hemodynamic compromise and donor age are strong risk factors in many studies.
The histopathology of the lungs in PGF is diffuse alveolar damage. The level of the inflammatory cytokine interleukin-8 in lung tissue 2 hours after reperfusion is strongly correlated with lung compliance, patient oxygenation, and outcome. 7 In some but not all studies, there appears to be a correlation between PGF and both acute and chronic allograft rejection.
Clinical diagnosis of PGF due to reperfusion injury requires exclusion of other causes of hypoxemic respiratory failure. It is critically important to evaluate the possibility of technical complications such as pulmonary vascular anastomotic stenosis or thrombosis. As well, hyperacute rejection due to circulating antidonor HLA antibodies should be considered if graft dysfunction begins within minutes of implantation and if the recipient has a history of pregnancy or blood transfusions. In patients with PGF, there may be frothy pulmonary edema and a clinical and radiographic picture indistinguishable from ARDS. After excluding vascular and immunologic causes of respiratory failure, management involves ventilatory strategies identical to those used in patients with ARDS. There have been no published studies specifically examining the impact of low-tidal-volume ventilatory strategies, but the authors certainly endorse this approach. Although animal studies have demonstrated an amelioration of lung injury in animals preemptively treated with nitric oxide and artificial surfactant, it is unclear if the addition of these therapies after established lung injury improves outcome in humans. 8, 9 Nitric oxide is now so readily available and has a low risk of complication that its routine use in this situation is a practice with which these authors would never argue.
Recent Developments
In the United States, most programs have changed the preservation solution used at the time of lung harvest to a new formulation, Perfadex, which has improved outcomes, thereby lessening the incidence of PGF. 10, 11 Also, in recent years, the increasing use of flexible bronchoscopy in and aggressive cardiopulmonary management of prospective donors have increased the number and quality of procured lungs. 12, 13 Last, it has become routine to treat prospective organ donors with high doses of methylprednisolone to address the hormonal failure common to brain death, which may also decrease the incidence of PGF.
14

Early Nosocomial Pneumonia
Deceased donors are individuals with brain death in whom family members make the difficult and generous decision to offer organs for transplantation. These individuals have typically had an endotracheal tube in place for days since admission to the hospital with a central nervous system crisis. Many of these individuals with evolving cerebral edema may have had routine suctioning of the airway omitted to lessen the chance of progressive central nervous system pressure spikes. Not surprisingly, many donors have atelectasis and hospital-acquired lower respiratory infections. In a particularly thorough study from Australia, Gabbay et al 12 found 38% of such donors with pulmonary infections severe enough to prohibit transplantation. Other studies, which have examined the outcome of transplantation of organs using more modest evidence of infection such as positive gram stain, have shown mixed results from increased serious infections in the recipient to no increase in graft failure. 
Recent Developments
There appears to be an increasing emphasis within many transplant programs and locales around the world for a more aggressive and detailed assessment and manage- 
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Clinical Pulmonary Medicine • Volume 12, Number 4, July 2005 ment of potential organ donors. Organs from "marginal donors" are more frequently being accepted and transplanted. 13 Pertinent aspects of donor management involve routine systemic corticosteroids, carefully selected but aggressive antibiotic therapy, and hormonal replacement. Early results are encouraging.
12,13
Acute Allograft Rejection
Acute graft rejection (AGR) occurs in approximately half of all lung-transplant recipients. It is manifest by subtle, nonspecific symptoms and can be definitively diagnosed only by biopsy of the lung tissue ( Table 2 ). Transbronchial biopsy is the biopsy method of choice in patients who are clinically stable. The histopathologic picture of AGR always involves the circumferential perivascular infiltration by lymphocytes. 15 Both CD4 ϩ and CD8 ϩ lymphocytes are present as a rule. In more severe degrees of rejection, the infiltrate may extend into the interstitium and around the airways.
AGR most commonly occurs within days of engraftment but can commonly occur throughout the early months after transplantation. Clinical symptoms are nonspecific and may include low-grade fever, malaise, bilateral inspiratory crackles, and a modest reduction in oxygenation and lung function. Most episodes of AGR can be treated effectively with the use of a 3-day course of high-dose intravenous corticosteroids. Nevertheless, repeated episodes of AGR are statistically the strongest predictor of chronic rejection in the form of bronchiolitis obliterans (BO). 16 With repeated AGR or steroid-resistant rejection, a change in the basic immunosuppressant regimen is often considered. Among the most straightforward options are maximizing doses of current immunosuppressants (if feasible), the change of cyclosporine to tacrolimus, and/or the change of azathioprine to mycophenolate mofetil. Many physicians will employ cytolytic therapy in this situation in the form of OKT3 or another antilymphocyte globulin preparation over a 7-to 14-day course. Other less commonly employed options are a 6-week course of once-weekly methotrexate at (0.15 to 0.25 mg/kg/wk), total lymphoid irradiation, or photopheresis.
Recent Developments
There appears to be a shift in front-line immunosuppression in recent years to tacrolimus in lieu of cyclosporine and mycophenolate mofetil in lieu of azathioprine. 2, 3 Recently, the availability of sirolimus provides a new agent with a novel mechanism of action in the event of refractory acute rejection. Studies in renal transplantation are encouraging in this regard. 17 However, severe bronchial anastomotic complications have been reported with use of sirolimus in the first few weeks after surgery and appear to put this agent in a second line of consideration or rescue role after repeated episodes of AGR at present. 18 Although logical as an early prophylactic strategy, aerosolized cyclosporine is not yet commercially available, nor has it been formally studied in this regard. More important, new immunosuppressive agents designed to induce immune tolerance may permit much more effective lung engraftment with lower-dose maintenance immunosuppression.
Infection
Infection is common in lung-transplant recipients because of the vulnerability of the graft and the need for immunosuppression. The most important pathogens are summarized in Table 3 . Factors which account for the high incidence of graft infection after lung transplantation include (a) exposure to microorganisms due to anatomic design; (b) the intrinsic frequency of community-based respiratory Children are probably at greater risk than adults because they have often not had primary infection with a number of important viruses at the time of transplantation and because community viruses tend to run at higher frequency and higher density within the social contacts of infants, children, and adolescents compared with adults. Specific diagnosis is crucially important in the effective treatment of lung transplant recipients. If a convincing sputum specimen cannot be easily obtained or there is significant morbidity, bronchoscopy with bronchoalveolar lavage is strongly recommended.
In CF patients, because the transplant effectively replaces bronchial epithelial cell population with non-CF cells beyond the bronchial anastomoses, there will be no exaggerated IL-8 secretion and increased binding of Pseudomonas aeruginosa to the epithelial cell membrane that is the norm in CF patients. 19 However, because the trachea and paranasal sinuses have epithelial cells deficient in cystic fibrosis transmembrane regulator protein, there is always the propensity for an increase in the prevalence of gram-negative organisms in the vicinity and superinfection in the graft to take place. A high index of suspicion for infection is critical to the posttransplant care of all of these patients.
Lower respiratory infection may be subtle in clinical presentation. Patients often have no fever and little cough. A drop in lung function is a particularly sensitive way of monitoring these patients for both infection and rejection. It is the authors' preference and practice that all lung transplant recipients have home spirometers for daily monitoring in the early months after transplantation. We consider a 10% drop in FEV1 from previous baseline to be a strong indication for physician reevaluation.
With respect to viral infections, we will begin with the herpes family viruses. There are subtleties in the diagnosis and treatment of cytomegalovirus (CMV) infection and significant variations in protocols among transplant centers beyond the scope of this paper. 20 Primary infection with CMV is more likely to be associated with actual disease than reactivation of latent infection. "CMV disease" is a term reserved for clinically detectable organ dysfunction due to CMV infection. If the donor serology was positive for CMV at the time of transplant and the recipient was IgG negative for CMV, there is a high chance of primary infection with disease, usually in the second to third month posttransplant. Pharmacologic options include preemptive or therapeutic uses of CMV-hyperimmune globulin, intravenous ganciclovir, intravenous foscarnet, and/or oral valganciclovir. With increasingly accurate methods of early diagnosis permitting timely treatment, morbidity in lung transplant recipients due to CMV infection and disease has diminished significantly in recent years.
Herpes simplex and varicella pneumonia are commonly seen concomitantly with cutaneous manifestations of these infections, which facilitates diagnosis. Acyclovir or valacyclovir therapy is effective, especially when provided early in the course of infection. Dosing is considerably higher in the treatment of varicella compared with herpes simplex infection.
Primary Epstein-Barr virus (EBV) infection is most common in children in whom their own serologic status is negative at transplant and the donor is serology positive. Early primary EBV infection in the transplant recipient is a risk factor for posttransplant lymphoproliferative disease (PTLD). 21 Since the first therapeutic measure in response to PTLD is usually a reduction in immunosuppression, survival after PTLD has been complicated by a high and early incidence of BO syndrome (BOS). Clinical scientists have developed the ability to grow clones of recipient EBV-specific cytotoxic T lymphocytes for therapeutic use in PTLD. 22 The availability of rituximab (anti-CD20 antibody) shows early promising results, which may lead to a significant lowering in morbidity and mortality. 23 With respect to respiratory viral infections, rapid diagnosis and consideration of specific antiviral therapy is strongly indicated, especially during the winter months. Among antiviral agents used include amantadine, oseltamivir, zanamivir, acyclovir, and ribavirin. Cidofovir may have a place in the treatment of adenovirus infection, a particularly virulent pathogen in lung transplant recipients. 24 One of the most feared infections in the transplanted lung is Aspergillus fumigatus (AF). When a CF patient has either a history of allergic bronchopulmonary aspergillosis or any growth of AF in respiratory specimens in the 12 months prior to transplant, we believe that a preemptive therapeutic approach should be considered. Either intravenous amphotericin B or itraconazole can be used for the first few days or until the patient has been weaned from ventilatory support and can take oral medication. After intravenous antifungal therapy, the options are aerosolized amphotericin B, oral itraconazole, or oral voriconazole. The aerosolized route has the advantage of getting drug to the vulnerable and often ischemic proximal bronchial airway where AF invasion can take place within days of transplantation. The liposomal form of amphotericin B may be preferred over amphotericin B desoxycholate. 25 On the other hand, oral voriconazole, which is much more consistently bioavailable than itraconazole, can be continued with relative ease for an extended period of time. 26 The azole antifungal agents all competitively inhibit the hepatic excretion of cyclosporine and tacrolimus, leading to a marked increase in blood level unless there is a dosage change. In all lung recipients, it is wise to minimize exposure to construction sites, barns, caves, and other sites in nature where heavy concentrations of mold spores can be anticipated.
Mallory and Elidemir
Clinical Pulmonary Medicine • Volume 12, Number 4, July 2005
Pneumocystis carinii, recently reclassified as a fungus and renamed Pneumocystis jiroveci, has been largely eliminated as a pulmonary pathogen in lung-transplant recipients by chemoprophylaxis. Trimethoprim-sulfamethoxazole is a well-tolerated and effective agent, which may need to be continued long term or any time there is an augmentation in immunosuppression. 27 Alternatives include dapsone, inhaled pentamidine, and the newly available oral agent atovaquone.
Bacterial lower respiratory tract infections (LRI) are common after transplantation. Many CF lung transplant recipients demonstrate a propensity for recurrent P aeruginosa LRI and may be treated presumptively when the LRI is not serious or symptoms are consistent with previous infection. Inhaled antibiotics are often a highly effective and efficient choice in lung transplant recipients with mild infections due to the relative patency of the central airways. With recurrent pseudomonas LRI in CF patients, consideration for sinus surgery may be warranted. Both with selected CF patients and those with established BO, treatment and/or suppressive therapy with aerosolized antibiotics, including tobramycin, gentamicin, and/or colistin, can be a highly effective and cost-effective strategy. Gram-positive community-acquired pathogens are a lesser risk factor, and updated pneumococcal vaccine would be a wise and commonly overlooked choice.
New Developments
The number of antifungal and antiviral agents continues to increase, requiring clinicians to keep up with agents and potential drug interactions. Immunosuppressed transplant patients can get very ill very quickly. Early and specific diagnosis and utilization of new agents with attention to possible impact on the drug metabolism of immunosuppressive agents and nephrotoxicity are the keys to effective therapy (Table 4) .
Chronic Graft Rejection
BO is a chronic inflammatory and proliferative complication, most commonly due to chronic graft rejection, that is silent during its initial stages. It is also the most common cause of death from lung transplantation after the first 6 months and a contributing cause of death in many remaining cases. [2] [3] [4] 28 Precise and sensitive diagnosis at the earliest possible stage of BO would be important (Table 5 ).
In the early 1990s, it was appreciated that even with aggressive use of transbronchial biopsies, many patients would develop a progressive obstructive worsening on spirometry. On further evaluation with open lung biopsy or at autopsy, these patients virtually always had BO. In 1993, the Lung Rejection Study Group revised the criteria for diagnosis of chronic allograft rejection and introduced the term of BOS, which has recently been reformulated and published. 28 Although the application of BOS criteria is undoubtedly accurate in most patients, by the time there has been a 20% loss of FEV1 from a previous baseline, there has undoubtedly been major and irreversible loss of small airways. Investigators have been looking for earlier and stillsensitive indicators of small-airways disease. The lung is an organ that is relatively available for sampling. Bronchoalveolar lavage has been an available and tempting target for studies of immunologic activation. Examination of cells and cytokine profiles has been largely frustrating to date. A Belgian group has come up with a new method utilizing simultaneous inhalation of inert gases to detect inhomogeneity of ventilation, which has promise for very early detection of BOS. 29 In most centers, at the time of initial diagnosis of BOS, augmentation of immunosuppression is implemented, with many of the same maneuvers mentioned above in refractory acute rejection. Unfortunately, in most patients, the airway obstruction is relentlessly progressive, albeit on a highly variable timescale ending eventually in death. However, some patients live a good quality of life for years before ultimately succumbing to respiratory failure. Retransplantation is a controversial option since rapid recurrence of BO has been reported in many cases.
New Developments
The most important strategy in the treatment of BO would be its prevention. In that light, the trends and developments described above in relation to the prevention and treatment of acute allograft rejection would be expected to have an impact on the incidence and natural history of BO. Investigators at Duke have recently discovered a high incidence of often asymptomatic gastroesophageal reflux disease and have suggested that it might contribute to the airway injury that can lead to BO. 30 Further study is under way, and the relationship of GERD to the pathogenesis of BOS remains to be determined.
New and improved methods of detection of BO are a continuing focus of basic and clinical research. Animal investigations into the potential use of specific therapies to prevent airway fibrosis show some promise. With respect to other therapies, it has recently been reported that azithromycin may play a beneficial role in early BOS, presumably due to an immunomodulatory mechanism. 31 Last, there is preliminary evidence that the prescription of daily "statin" therapy may also have a favorable immunomodulatory impact on the development of BO. 
Bone Marrow Transplantation (BMT)
BMT is currently the treatment of choice for many hematologic malignancies and severe congenital or acquired disorders of the hematopoietic and immune systems in both childhood and adulthood. 33 In the past 10 years, the types of hematopoietic transplants have multiplied. Broadly speaking, "BMT" now includes stem cell and bone marrow transplants, both allogeneic (from a donor based on HLA matching) and autologous (harvested from self and reinfused after a bonemarrow-toxic therapy). The use of placental stem cell transplants remains rare. For reasons of simplicity, we will discuss the pulmonary complications, which occur in any of the above with specific comments when a particular type of transplant is predisposed to a given complication.
In the immediate pre-and post-BMT periods, recipients have profound immune impairment that results from the myeloablative effects of conditioning regimens. 34 Initially, there is virtually no adaptive and minimal innate immune function. Neutropenia, as one important aspect of innate immune function, usually lasts about 2 to 3 weeks. 35 Even after successful marrow engraftment, recovery of cellular and humoral immune function related to B and T lymphocytes gradually takes place over several months and is not complete until approximately 1 year. 34, 35 Pulmonary complications account for significant morbidity and mortality in patients following BMT, occurring in up to 70% of recipients, and are a factor in more than 30% of transplant-related deaths. [35] [36] [37] A screening pulmonary evaluation should be considered in all BMT candidates. Lung comorbidity is a major predisposing factor for posttransplant complications. Among important items in the candidate's history are previous pulmonary disease, a history of radiation therapy to the chest, and key environmental exposures (birds, cats, endemic fungal organisms). We will divide our discussion of pulmonary complications into infectious and noninfectious causes.
The course of immunosuppression after BMT is quite distinct from solid organ transplant patients in that there is a predictable and usually time-limited course of immunosuppression. In addition, since there is no risk of graft versus host disease (GVHD) in autologous BMT, there is significantly less immunosuppression in these patients than in those who receive allogeneic BMT. Logically then, the time course and details of any individual immunosuppressive regimen will be of enormous relevance in evaluating the patient with respiratory symptoms as these data will help to narrow the differential diagnoses to certain pulmonary complications that characteristically occur at particular times following BMT (Fig. 2) . [35] [36] [37] As with lung transplantation, early and specific diagnosis enables treatment of the pulmonary complications, which helps to minimize morbidity and mortality.
Time Course of Immune Dysfunction Following BMT
Understanding of possible causes of pulmonary disease after BMT requires having a thorough knowledge of immune dysfunction during this time period. The 3 important time periods following BMT are detailed in Table 6 . Conditioning regimens with chemotherapy and total body irradiation lead to initiation of immunosuppressed state usually a few days before BMT. 34 Severe neutropenia occurs in all patients during the neutropenic phase following BMT, but neutrophils are the first to recover, usually within 2 to 3 weeks following BMT. As indicated previously, the lymphocyte count and function take months to return to normal. Nearly all immune functions are impaired during the first several months. 34 In allogeneic or autologous BMT patients without GVHD, immunity generally returns to normal by 1 year following BMT.
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NEUTROPENIC PHASE (<30 DAYS)
Profound neutropenia usually occurs a week before BMT and extends for a period of 2-4 weeks. Partly because of the use of aggressive prophylactic antiviral and antifungal therapies and a low threshold for the use of antibiotics, most of the pulmonary complications derive from noninfectious etiologies during this period, with pulmonary edema and diffuse alveolar hemorrhage (DAH) being most common. 35, 36 During this period, neutropenia and damage to the integrity of mucosal membranes are the predominant defects in host defense, which predispose the patient to bacterial and fungal infections. 37 
New Developments
Many investigations into the pathogenesis and potential treatment of the vulnerability of the lung to severe invasive infection in the early neutropenic phase involve animal models. Among potential modalities of augmenting innate immunity in a murine model, Yang and coworkers 38 report that instillation of surfactant protein A into the tracheobronchial tree decreased inflammation and improved survival.
Noninfectious Pulmonary Complications
Pulmonary Edema
Due to infusion of large volumes of intravenous fluid, combined with cardiac and renal impairment secondary to chemotherapy, BMT patients frequently develop pulmonary edema during this period, reported in up to 65% patients. 37 In addition, the effects of radiotherapy, chemotherapy, and infections may also lead to capillary membrane leakage resulting in noncardiogenic pulmonary edema.
39
DAH
Years ago, DAH was initially seen in approximately 20% of autologous BMT, but is now less common. It has an associated mortality approaching 100%. 35 The exact cause of DAH is unknown, but the likely site is the pulmonary capillary network. However, since the onset of DAH often coincides with the engraftment period (7 to 21 days following BMT), some authors believe that it is due to influx of the neutrophils into the lung. 35, 36 If acute respiratory deterioration supervenes in the second to fourth week after BMT, it would be important to exclude infection, but endothelial cell injury in the presence of thrombocytopenia probably underlies most cases. Clinically, patients present with acute dyspnea, nonproductive cough, hypoxia, and fever. Frank hemoptysis is uncommon, and overt clinical signs may be subtle despite the rapid deterioration in radiographic appearance with diffuse alveolar infiltrates, a hallmark of the condition. Bronchoscopy is helpful in diagnosis and ruling out other possible causes of respiratory deterioration. Typically, in patients with DAH, bronchoalveolar lavage fluid becomes progressively bloodier with repeated lavage in the same area and contains Ͼ20% hemosiderin-laden macrophages. 40 Despite lack of good scientific evidence, high dose methylprednisolone (10 -15 mg/kg) is the treatment of choice at this time. 40 
New Developments
Recently, there was an anecdotal report of benefits of the addition of recombinant factor VIIa in an actual patient with DAH with apparent survival. 41 Clearly, there is a need for larger, more systematic study in this area.
Infections
Bacterial infections are common in the neutropenic phase with a reported incidence ranging from 20% to 50%. 39 Infections are caused by a variety of bacteria; sputum culture is not usually helpful. Bacteremia is common and frequently caused by gram-negative bacteria from gastrointestinal tract and/or oral mucosa. 42 Fortunately, death from bacterial infections is unusual at this stage owing to the usage of broad-spectrum antibiotics. 39 Respiratory viral infections can be devastating after BMT including influenza, respiratory syncytial virus, parainfluenza virus, and adenovirus. Compulsive surveillance via rapid diagnostic techniques and appropriate isolation are vital. Early consideration of antiviral therapy may be life saving, with approaches and therapies very similar to those covered in the above discussion on lung-transplant recipients.
Fungal infections are a common cause of pneumonia following BMT with a reported incidence of up to 70%. 43 The use of particulate air filter masks and laminar airflow rooms has decreased the incidence of fungal infections. 35 The most common pathogen is AF, seen in about 10% of patients. 34, 44 In the immunocompromised, Aspergillus may be angioinvasive, causing hemorrhagic infarction or airwayinvasive causing tracheobronchitis, bronchiectasis, or pneumonia. Often these clinical syndromes will overlap. The incidence of invasive fungal infection is higher in allogeneic (in comparison to autologous) transplants. Candida species and nocardia are seen less frequently. 44, 45 Clinically, patients with fungal infection may present with fever, dyspnea, dry cough, pleuritic pain, and sometimes hemoptysis, but early diagnosis before these features develop is important if treatment is to be successful. Plain chest radiographic findings include combinations of ill-defined nodules or masses with or without cavitation and focal areas of consolidation. On HRCT, early angioinvasive aspergillosis characteristically shows a nodule or mass surrounded by a halo of ground glass, known as the "CT halo sign," which represents hemorrhagic infarction around the consolidated fungal infection 46, 47 Cavitation of nodules appearing as an air-crescent sign on HRCT occurs during the recovery phase of the infection when the neutropenia is recovering. 48 Cavitation generally occurs 2 weeks after the appearance of nodules, usually with a white blood cell count of more than 1000 mm Ϫ3 , and is considered to be a good prognostic sign. 46, 47 In 15%-30% of patients with invasive aspergillosis, the fungus invades the airways. HRCT findings include patchy peribronchial or peribronchiolar consolidation areas and small centrilobular nodules. 49 -51 Surgical resection still plays an important role in selected patients. 49 Amphotericin B, or liposomal amphotericin if there is renal impairment, is currently the most commonly used antifungal treatments 51 Even with proper therapy, mortality of invasive aspergillosis can be as high as 90%. 51 
New Developments
Recently, new antifungal agents have become available and are proving useful in the treatment of serious fungal infection in BMT patients. Routine prophylactic use of oral azole antifungal agents is uncommon and controversial. 52 Caspofungin and voriconazole are new agents (Table 5) , both of which show good efficacy against invasive fungal disease with less renal toxicity than amphotericin. 53, 54 Synergistic combinations of antifungal agents are being increasingly employed. Furthermore, a sensitive PCR for Aspergillus is becoming available and may be particularly useful in the early diagnosis of systemic aspergillosis in these patients. 54 The aggressive use of antiviral therapy and passive immunotherapy, such as palivizumab for RSV infection, is being studied in the BMT population. 55 Despite anecdotal reports of success, definitive studies are yet to be done. In the short run, aggressive infection control policies, routine immunization, and the early use of antiviral agents should be considered in this vulnerable population.
EARLY PHASE (30 -100 DAYS)
This phase occurs between 30 days and 100 days following BMT. Immunosuppression is due to an underlying deficit of cellular-and humoral-mediated immunity and may be severe if there is GVHD requiring treatment with immunosuppressive agents. The gradual improvement in number and function of neutrophils is associated with a decreasing incidence of fungal infections, but on the other hand, there is an increasing incidence of viral infections.
Noninfectious Complications Engraftment Syndrome (Idiopathic Pneumonia Syndrome)
ES, or IPS, is defined as diffuse lung injury beyond 30 days following BMT in the absence of infectious organisms. 55, 56 Pathologically, it represents a form of diffuse alveolar damage and is a diagnosis of exclusion. Clinically, the patient presents with rash, dyspnea, fever, nonproductive cough, and hypoxemia. 57 The chest radiographic findings include bilateral pleural effusions, transient pulmonary infil-
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trates, and interstitial pulmonary edema. At present, there is no effective treatment of ES. Supportive treatment includes oxygen supplementation, diuretics, and corticosteroids. The mortality rate can be as high as 70%.
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New Developments
Animal models have yielded clues in the complex interaction of cytokines to suggest possible therapeutic targets of future therapies. 59 The currently available biologic product etanercept has been reported in a small case series to have a measurable benefit in the treatment of IPS. 60 Further studies are awaited.
Infectious Pulmonary Complications
CMV and P jiroveci pneumonia are more frequently present in the early phase post BMT between 30 days and 100 days but may occur earlier. CMV infections used to occur in up to 70% of patients following BMT. Before the introduction of aggressive preemptive antiviral therapy, CMV pneumonitis was an important pulmonary complication and occurred in up to 40% patients, often between 6 weeks and 12 weeks following BMT. 39, 61 It is of considerable clinical importance in all types of allogeneic BMT, 61 and once pneumonitis developed, there was a mortality rate of about 85%. 62 The infection is normally caused by reactivation of the latent virus from the recipient or the donor during profound immunosuppression, but it can also be caused by infusion of CMV-positive blood products if these are not screened and excluded. The serologic status of both donor and recipient is routinely tested prior to allogeneic BMT. A CMV titer Ͼ1:16 in the recipient indicates previous infection with CMV and a risk of reactivation after BMT. If negative in the recipient but positive in the donor, there is a high risk of primary CMV infection after BMT. In the recipient-positive situation, survival is enhanced via weekly CMV antigenemia or PCR studies followed by preemptive treatment, especially if the copy numbers are high or rising, with ganciclovir or foscarnet. 62 If treatment is delayed until the patient presents clinically with shortness of breath, fever, nonproductive cough, and hypoxia or with pneumonitis, therapy is unlikely to be successful. 37, 61 In the serology mismatch situation, preemptive therapy from the early post-BMT period is a common approach.
Plain radiographic findings in CMV pneumonitis include areas of diffuse ground-glass change and nodules, mainly in the mid and lower zones. 63 HRCT findings include multiple micronodules and associated areas of consolidation or ground-glass attenuation. 63 P jiroveci infection has been virtually eradicated following the introduction of routine trimethoprim-sulfamethoxazole prophylaxis. 38, 64 It is mainly present in patients who are unable to tolerate prophylactic medication or are nonadherent to therapy. Clinical presentation is similar to other causes of acute LRTI. The characteristic HRCT finding is ground-glass attenuation, which may be diffuse, predominantly perihilar, or patchy in distribution. 65 There may be atypical distribution in patients on prophylaxis. Diagnosis can be made by evaluation of BAL fluid under the microscope after staining with special stains such as toluidine blue-O or methenamine silver. Treatment of choice is IV trimethoprim-sulfamethoxazole for at least 2 weeks. IV Pentamidine is an alternative for patients who cannot tolerate trimethoprim-sulfamethoxazole. With appropriate treatment, prognosis is better, mortality ranging between 5% and 40%.
LATE PHASE (>100 DAYS)
This phase occurs after 100 days following BMT. The BMT patient's immune system usually recovers to normal by the end of first year. Most pulmonary complications are noninfectious. They include BO, cryptogenic organizing pneumonia (COP) and chronic GVHD. 37, 38 Lung biopsy is often necessary to establish a definitive diagnosis.
Infectious pulmonary complications are uncommon during this period except in the presence of GVHD associated with EBV infection. BMT patients with GVHD have impaired immune systems, and this is further compromised with immunosuppressive therapy, predisposing them to bacterial and viral infections.
37,38
Noninfectious Complications BO
The prevalence of BO is difficult to ascertain after BMT. As discussed earlier, because BO after lung transplantation can be so subtle from a clinical and histopathologic point of view, the lung-transplant community has adopted a clinical scoring system, heavily dependent on serial lung function testing. 28 This kind of follow-up is not performed in most BMT centers. Therefore, it is not surprising that studies demonstrate a prevalence of BO after BMT from 2% to 10%. 66 The first manifestations are usually seen within 6 months to 12 months following BMT. 36, 43 It rarely, if ever, occurs after autologous transplantation. 36 The pathogenesis of BO after BMT is complex and probably multifactorial. Most cases are thought to be secondary to bronchial mucosal damage from GVHD, with inflammation of the small airways and subsequent fibrogenesis and obliteration. The histopathology is identical to the form of BO seen after lung transplantation. The published mortality rate of BO after BMT ranges from 40% to 90%. The lower rate of BO after BMT compared with lung transplantation would be consistent with a self-limited injury and less of a relentlessly progressive process. 35 Unfortunately, there are no large carefully documented series of BMT recipients with BO, which has followed a cohort of such patients for many years. In affected individuals, the patient develops a nonreversible airflow obstruction with increasing nonproductive cough and dyspnea, or there may just be an asymptomatic deterioration in pulmonary function tests. 36, 37 Chest radiograph findings may be minimal, or there may be signs of hyperinflation, recurrent pneumothoraces, and occasional focal/diffuse opacities. HRCT shows bronchial dilatation, bronchial wall thickening, peripheral vascular pruning, and mosaic lung attenuation with air trapping on expiratory scans. 39 Some patients apparently have clinical stability for many years. Currently, although there have been trials with thalidomide and other agents, there is no clearly effective medical therapy. If the underlying disease has been effectively cured, lung transplantation has been successfully performed to treat BO after BMT.
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COP
This is a common late complication, and in most cases the exact etiology is unknown. 68 Clinically, patients present with a nonproductive cough, low-grade fever, and dyspnea. Chest radiography shows patchy consolidation in multiple lobes. HRCT characteristically demonstrates patchy consolidation particularly with a peribronchovascular and/or a peripheral distribution in immunocompetent patients. In immunocompromised patients following BMT, ground-glass attenuation and nodules are a more frequent finding, usually more randomly distributed. The nodules generally have smooth, well-defined margins. 39, 68 Sometimes this nodular appearance may be related to COP-like reaction to an underlying infection or secondary to drug therapy. Treatment is with steroids, 68 and most patients respond with resolution of infiltrates.
Chronic GVHD
GVHD is a result of immune reaction of immunocompetent donor cells against host antigens and occurs in up to 50% of patients who survive longer than 6 months. 37 In most patients, chronic GVHD follows acute GVHD. Patients with pulmonary GVHD may also have disease elsewhere, particularly in the skin, liver, gastrointestinal tract, and sinuses. The pulmonary complications include recurrent lung infections, chronic aspiration, BO, and lymphoid interstitial pneumonia. 37 Other conditions occur rarely such as posttransplantation lymphoproliferative disorder associated with EBV infection, including lymphoid hyperplasia and lymphoid interstitial pneumonia.
CONCLUSION
Pulmonary complications are important causes of mortality and morbidity after BMT. Timely and aggressive diagnostic workup in conjunction with appropriate treatment is vital in management of these complications. Many of the newer medications noted in Table 4 have been implemented in the care of BMT patients. It appears that many oncologists in the field are hoping to mitigate the pulmonary complications associated with BMT by exploring the new frontiers of stem cell transplantation. In the meantime, many patients continue to suffer the pulmonary complications we have discussed here.
The care of patients after BMT has generally been delivered in physically segregated units by devoted staffs of nurses and oncology physicians. Although the acuity of these patients is impressively high, consultation with other subspecialists seems to be less common than in equally ill patients in general intensive care units. Clearly, clinical pharmacists and infectious disease specialists have been intimately involved with oncologists in integrating new approaches to immunosuppression and antimicrobial therapy in the ongoing effort to optimize the care of patients after BMT. We hope that a greater number of BMT centers will model a care philosophy, which includes a pro-active and regularly scheduled partnership with pulmonary physicians. For instance, the use of flexible bronchoscopy, a widely available diagnostic tool, before introducing every class of antimicrobial agent would seem to be a cost conscious and likely effective way of targeting expensive therapies that have important side effects. Furthermore, serial lung-function testing would undoubtedly be helpful in detecting the chronic, slowly developing pulmonary complications of BMT. Recent developments in radiologic diagnosis will undoubtedly improve diagnostic accuracy in the future. We sincerely believe that an early and aggressive approach to diagnosis of pulmonary complications, facilitated by a close working relationship among BMT physicians, radiologists, surgeons and pulmonologists, will be life saving.
